Objective:To investigate the use of antibacterial in our hospital in 2004-2006 and analyze its features and tendency so as to provide references for the rational use.Method:The stocked data of antibacterial from 2004-2006 were collected by the computer management system.The DDDs of antibacterial in our hospital were classified and analyzed according to the defined daily dose(DDD).Result:The ratio of the antibacterial costs in the annual drug consumption sum was decreased year by year.The average ratio was 17.01%in three years,lower than the 27.97%,which was the average of total hospitals in China.The DDDs of quinolones in our hospital had been dominating the first place in 2004～2006,and the average increase was 14.1%in three years.The second was cephalosporins with 13.61%of its average increase,similar to quinolones,but its consumption sum was more than that of quinolones.Conclusion:The use of antibacterial in our hospital in 2004-2006 was rational on the whole.

OBJECTIVETo evaluate the clinical efficacy and safety of angong niuhuang pill (ANP) as an adjuvant treatment on moderate or severe neonatal hypoxic-ischemic encephalopathy (NHIE).

METHODSThirty-nine neonates with NHIE in the control group were treated with conventional treatment, and 58 in the treated group were administered orally ANP additionally, and relative indexes were observed.

RESULTSThe improvement of aspects such as recovery of consciousness, muscular tension, and primitive reflex and disappearance of convulsion, in the treated group was better than that in the control group (P < 0.01).

CONCLUSIONANP as an adjuvant treatment has a definite effect on NHIE, it can promote the recovery of patients, decrease the occurrence of sequelae and with high safety, therefore, is a drug feasible for clinical application.

Asphyxia Neonatorum ; complications ; drug therapy ; Drug Therapy, Combination ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Humans ; Hypoxia-Ischemia, Brain ; drug therapy ; etiology ; Infant, Newborn ; Male ; Phytotherapy

The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 has rapidly spread globally. Cancer patients are at a higher risk of being infected with the coronavirus and are more likely to develop severe complications, as compared to the general population. The increasing spread of COVID-19 presents challenges for the clinical care of patients with gynecological malignancies. Concerted efforts should be put into managing gynecological malignancies in an orderly manner by strictly implementing the measures that are specifically developed for controlling the spread of COVID-19. We have drafted Recommendations on Management of Gynecological Malignancies during the COVID-19 Pandemic based on our experience on controlling COVID-19 pandemic in China. We recommend that patients with gynecological malignancies should be managed in hierarchical and individualized manners in combination with local conditions related to COVID-19. Medical care decision should be balanced between controlling COVID-19 pandemic spread and timely diagnosis and treatment for gynecologic oncology patients.